Diabetes: From Insulin Discovery to A1c Testing
One session will mark key milestones in diabetes diagnosis and management. The program will reference the discovery of insulin in 1921, a breakthrough that transformed a once-fatal disease into a manageable chronic condition. It will also highlight the development of hemoglobin A1c testing in the 1970s, which gave clinicians a reliable measure of long-term blood glucose control. Together, these advances have shaped modern diabetes care, enabling earlier intervention and more precise monitoring. The session underscores how laboratory medicine has driven progress against a condition affecting millions in the United States and worldwide.
Space Diagnostics: Bringing Lab Testing to Orbit
Another featured topic is space diagnostics, which refers to the adaptation of laboratory testing for use in spaceflight. Research conducted on the International Space Station, operational since 1998, has been central to this effort. The ability to run medical tests in microgravity is critical for astronaut health during long-duration missions. It also has implications for Earth-based care, as compact, ruggedized testing systems developed for space can be deployed in remote or resource-limited settings. The ADLM session will examine how these technologies are being refined to operate reliably beyond our planet.
Alzheimer’s and Down Syndrome: A Genetic Link Under the Microscope
The program will also cover the linkage between Alzheimer’s disease and Down syndrome, a connection grounded in genetics. Individuals with Down syndrome have an extra copy of chromosome 21, which carries the gene for amyloid precursor protein. That extra gene copy leads to the early onset of Alzheimer’s pathology. Studies show that by age 40, nearly all individuals with Down syndrome have Alzheimer’s-related brain changes. This knowledge is reshaping early detection efforts for a disease that creates heavy social and economic burdens for caregivers. Alzheimer’s is the most frequent cause of dementia, typically beginning with difficulty remembering recent events. As the disease progresses, patients often experience disorientation, mood swings, and language problems, eventually leading to loss of bodily functions and death. It is characterized by the buildup of neurofibrillary tangles and amyloid plaques in the cerebral cortex, protein aggregates that disrupt cell function, causing neurons to degenerate and synaptic connections to vanish. While genetic factors and environmental risks like head injuries or high blood pressure contribute to its development, the exact causes remain poorly understood. Diagnosis once required a postmortem brain examination; modern neuroimaging and fluid biomarkers now allow for diagnosis in living patients. No current treatments can reverse or stop progression, though some therapies may temporarily ease symptoms, and physical activity along with a healthy diet can help reduce the risk of cognitive decline. Because initial symptoms are often mistaken for normal aging, early detection remains a priority for medical science.
Cancer Screening Advances: Liquid Biopsy and Multi-Cancer Tests
Finally, the meeting will cover advances in cancer screening and biomarkers. This includes liquid biopsy technologies that detect circulating tumor DNA in blood samples, allowing for noninvasive monitoring of cancer. Also featured are multi-cancer early detection tests, known as MCED tests, which are being studied in clinical trials such as the NHS-Galleri trial in the United Kingdom, launched in 2021. These tests aim to catch multiple types of cancer at earlier, more treatable stages. The ADLM session will highlight how such innovations could expand screening beyond current single-organ approaches. The organization emphasizes that these developments are part of its broader mission to advance clinical laboratory science. Readers are advised to consult their doctor for medical advice.
